Epofer Injection contains Recombinant Human Erythropoietin Alfa at a concentration of 4000 IU/ml, a hematopoietic growth factor used to stimulate erythropoiesis. It is indicated for the treatment of anemia associated with chronic kidney disease (CKD), including patients on dialysis and those not yet on dialysis. Additionally, Epofer is utilized to manage anemia in patients undergoing chemotherapy for non-myeloid malignancies, reducing the need for blood transfusions. The mechanism of action involves binding to erythropoietin receptors on erythroid progenitor cells in the bone marrow, promoting their proliferation and differentiation into mature red blood cells, thereby increasing hemoglobin levels and improving oxygen delivery to tissues. Epofer Injection is administered via subcutaneous or intravenous routes, with dosing individualized based on patient response and hemoglobin targets. Monitoring of hemoglobin concentration is essential to avoid excessive erythropoiesis and potential complications such as hypertension, thromboembolic events, or pure red cell aplasia. Contraindications include uncontrolled hypertension and hypersensitivity to the active substance or any excipients. Caution is advised in patients with risk factors for cardiovascular events. Epofer Injection should be used under strict medical supervision with regular hematologic and clinical assessments to ensure efficacy and safety.